IDH1 and chondrosarcoma: IDH1/2 mutations were found in 71% of conventional chondrosarcomas and 57% of dedifferentiated chondrosarcomas [4, 5], as well as in gliomas and acute myeloid leukemia [6, 7], suggesting a potential role for aberrant IDH function in the pathogenesis of these malignancies.